Targeted drug poziotinib tested in rare lung cancer mutations
NCT ID NCT03066206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are limited, but poziotinib works by blocking enzymes that cancer cells need to grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Poziotinib (a targeted drug that blocks enzymes helping cancer cells grow)
- What this could lead to
- If successful, poziotinib could offer a new treatment option for people with hard-to-treat lung cancers that have specific genetic mutations.
- What could go wrong
- This trial was terminated early, so we have less data than planned. The drug may not work for everyone and can cause side effects like rash or diarrhea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR EXON 20 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?